Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1353-1357

  Katsumata, N ^a   Hirai, Y ^b   Kamiura, S ^c   Sugiyama, T ^d   Kokawa, K ^e   Hatae, M ^f   Nishimura, R ^g   Ochiai, K ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

^e WAKAYAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f Kagoshima City Hospital   (Japan)

^g HYOGO CANCER CENTER   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cervical cancer; Chemotherapy; Phase II trial; Relapse; S 1

Indexed keywords

FLUOROURACIL DERIVATIVE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; LEUKOPENIA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR LOCALIZATION; UTERINE CERVIX CANCER; VOMITING;

EID: 79957800354     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq602     Document Type: Article

References (33)

1. Shirasaka T, Shimamato Y, Ohshimo H. et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557.
2. Inuyama Y, Kida A, Tsukuda M. et al. [Late phase II study of S-1 in patients with advanced head and neck cancer]. Gan To Kagaku Ryoho 2001; 28: 1381-1390.
3. Kawahara M, Furuse K, Segawa Y. et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001; 85: 939-943.
4. Koizumi W, Kurihara M, Nakano S. et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58: 191-197.
5. Ohtsu A, Baba H, Sakata Y. et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000; 83: 141-145.
6. Saeki T, Takashima S, Sano M. et al. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer]. Gan To Kagaku Ryoho 2004; 31: 539-547.
7. Shirao K, Ohtsu A, Takada H. et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004; 100: 2355-2361.
8. Ueno H, Okusaka T, Ikeda M. et al. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004; 91: 1769-1774.
9. Ueno H, Okusaka T, Ikeda M. et al. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005; 68: 171-178.
10. Therasse P, Arbuck SG, Eisenhauer EA. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
11. Curtin JP, Blessing JA, Webster KD. et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001; 19: 1275-1278.
12. Kudelka AP, Winn R, Edwards CL. et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997; 8: 657-661.
13. McGuire WP, Blessing JA, Moore D. et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 792-795.
14. Bookman MA, Blessing JA, Hanjani P. et al. Topotecan in squamous cell carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 77: 446-449.
15. Muderspach LI, Blessing JA, Levenback C. et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001; 81: 213-215.
16. Irvin WP, Price FV, Bailey H. et al. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer 1998; 82: 328-333.
17. Verschraegen CF, Levy T, Kudelka AP. et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15: 625-631.
18. Lhomme C, Vermorken JB, Mickiewicz E. et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer 2000; 36: 194-199.
19. Morris M, Brader KR, Levenback C. et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998; 16: 1094-1098.
20. Muggia FM, Blessing JA, Method M. et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 639-643.
21. Garcia AA, Blessing JA, Darcy KM. et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study. Gynecol Oncol 2007; 104: 572-579.
22. Jenkins AD, Ramondetta LM, Sun C. et al. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 2005; 97: 840-844.
23. Cervellino JC, Araujo CE, Pirisi C. et al. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study. Cancer Chemother Pharmacol 1990; 26 (Suppl): S1-S3.
24. Sutton GP, Blessing JA, Adcock L. et al. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. Invest New Drugs 1989; 7: 341-343.
25. Sutton GP, Blessing JA, McGuire WP. et al. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993; 168: 805-807.
26. Long HJ III. Management of metastatic cervical cancer: review of the literature. J Clin Oncol 2007; 25: 2966-2974.
27. Monk BJ, Sill M, McMeekin DS. et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group (GOG) study. J Clin Oncol (Meeting Abstracts) 2008; 26: LBA5504.
28. Scanlon KJ, Newman EM, Lu Y. et al. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A 1986; 83: 8923-8925.
29. Shirasaka T, Shimamoto Y, Ohshimo H. et al. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-172.
30. Fujii M. [Combination therapy with S-1 and CDDP for head and neck cancer]. Gan To Kagaku Ryoho 2006; 1 (33 Suppl): 150-154.
31. Ichinose Y, Yoshimori K, Sakai H. et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multiinstitutional phase II trial. Clin Cancer Res 2004; 10: 7860-7864.
32. Koizumi W, Tanabe S, Saigenji K. et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89: 2207-2212.
33. Koizumi W, Narahara H, Hara T. et al. S-1 plus cisplatin versus S-1 alone for firstline treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.